Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL

Aaron T. Gerds, Ruben Mesa, John M. Burke, Michael R. Grunwald, Brady L. Stein, Peg Squier, Jingbo Yu, J. E. Hamer-Maansson, Stephen T. Oh

Blood (2024) 143 (16): 1646–1655.

https://doi.org/10.1182/blood.2023020232

Published: 2024

Includes: Supplemental data

Journal Articles

Neighborhood Disadvantage Is Associated with Inferior Overall Survival for Acute Myeloid Leukemia Patients Treated with Standard Intensive Induction

Brittany Knick Ragon, Danielle Boselli, Rupali Bose, Stephanie Begley, Melissa Aguiar, Kris Blackley, Nilay Shah, Aleksander L. Chojecki, Srinivasa Reddy Sanikommu, Yifan Pang, Jing Ai, Belinda Avalos, Edward A. Copelan, Thomas G. Knight, Michael R. Grunwald

Blood (2023) 142 (Supplement 1): 3799.

https://doi.org/10.1182/blood-2023-179352

Published: 2023

Journal Articles

MYC Pathway Upregulation Identified in Non-Responders to Hypomethylating Agents and Presents a Therapeutic Target in Acute Myeloid Leukemia

Brittany Knick Ragon, Margaret D. Templeton, Sara L. Seegers, Jenny Chen, Hsih-Te Yang, Thomas G. Knight, Jing Ai, Edward A. Copelan, Belinda Avalos, Nury M. Steuerwald, Jian Jin, Gang Greg Wang, Steven I. Park, Jai N. Patel, Michael R. Grunwald, Lawrence J. Druhan

Blood (2023) 142 (Supplement 1): 5741.

https://doi.org/10.1182/blood-2023-179318

Published: 2023

Journal Articles

High Rate of Disease Progression in Patients with Low-Risk Myelofibrosis (MF) Enrolled in the Prospective, Real-World MOST Study

Michael R. Grunwald, Aaron T. Gerds, Apurv Agrawal, Evan M. Braunstein, JE Hamer-Maansson, Tricia Kalafut, John Mascarenhas

Blood (2023) 142 (Supplement 1): 3803.

https://doi.org/10.1182/blood-2023-174523

Published: 2023

Journal Articles

Socioeconomic Disadvantage Is Associated with Decreased Long-Term Survival in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia

Allison Verbyla, Danielle Boselli, Brittany Knick Ragon, Jing Ai, Lawrence J. Druhan, Meng-Yun Lin, Michael R. Grunwald, Amresh Hanchate, Thomas G. Knight

Blood (2023) 142 (Supplement 1): 2391.

https://doi.org/10.1182/blood-2023-182299

Published: 2023

Journal Articles

A Real-World Evaluation of Risk Factors for Disease Progression in Patients with Polycythemia Vera (PV) Enrolled in REVEAL

Michael R. Grunwald, Jeffrey I. Zwicker, Aaron T. Gerds, John M. Burke, Zhenyi Xue, Erin L. Crowgey, Justine Carl, Patricia Feldman, Evan M. Braunstein, Stephen Oh

Blood (2023) 142 (Supplement 1): 385.

https://doi.org/10.1182/blood-2023-180215

Published: 2023

Journal Articles

Enhanced Support Services Including Nurse Navigation Mitigate Socioeconomic Disparities in the Treatment of Patients with Acute Lymphoblastic Leukemia

Thomas G. Knight, Danielle Boselli, Allison Verbyla, Jing Ai, Aleksander L. Chojecki, Nilay Shah, Yifan Pang, Lawrence J. Druhan, Edward A. Copelan, Michael R. Grunwald, Brittany Knick Ragon

Blood (2023) 142 (Supplement 1): 5078.

https://doi.org/10.1182/blood-2023-182371

Published: 2023

Journal Articles

A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia

Amir T. Fathi, Geoffrey G Fell, Areej El-Jawahri, Alexander E. Perl, Brian A. Jonas, Ajoy L. Dias, Alice S. Mims, Uma Borate, Brittany Knick Ragon, Michael R. Grunwald, Mary Linton B. Peters, Timothy A. Graubert, Philip C. Amrein, Hanno R. Hock, Andrew M. Brunner, Gabriela S. Hobbs, Rupa Narayan, Donna S. Neuberg, Ibrahim Aldoss

Blood (2022) 140 (Supplement 1): 3284–3286.

https://doi.org/10.1182/blood-2022-162525

Published: 2022

Journal Articles

Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation

Brittany Knick Ragon, Danielle Boselli, Rupali Bose, Stephanie Begley, Melissa Aguiar, Kris Blackley, Nilay A. Shah, Aleksander L. Chojecki, Srinivasa Reddy R. Sanikommu, Jing Ai, Lawrence J Druhan, Nury M Steuerwald, Jai N Patel, James T. Symanowski, Belinda R. Avalos, Edward A. Copelan, Derek Raghavan, Thomas G. Knight, Michael R. Grunwald

Blood (2022) 140 (Supplement 1): 10993–10995.

https://doi.org/10.1182/blood-2022-159179

Published: 2022

Journal Articles

Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

Blood (2022) 140 (Supplement 1): 7731–7733.

https://doi.org/10.1182/blood-2022-157985

Published: 2022

Journal Articles

Disease Progression and Leukemic Transformation in Patients With Lower-Risk Myelofibrosis (MF): An Analysis from MOST

Rami S. Komrokji, Michael R. Grunwald, Evan Braunstein, J.E. Hamer-Maansson, Patricia Kalafut, John Mascarenhas

Blood (2022) 140 (Supplement 1): 6832–6834.

https://doi.org/10.1182/blood-2022-159181

Published: 2022

Journal Articles

Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL

Aaron T. Gerds, Michael R. Grunwald, Stephen T. Oh, Evan Braunstein, Zhenyi Xue, Valkal Bhatt, Jingbo Yu, Ruben Mesa

Blood (2022) 140 (Supplement 1): 6810–6812.

https://doi.org/10.1182/blood-2022-158144

Published: 2022

Journal Articles

Measuring the Incidence of Distress and Supportive Oncology Utilization Among Patients with Myeloproliferative Neoplasms: A Single Center Experience

Rushil V. Patel, Danielle Boselli, Patrick L Meadors, Stephanie Begley, Rupali Bose, Jing Ai, Brittany Knick Ragon, Srinivasa Reddy R. Sanikommu, Nilay A. Shah, Thomas G. Knight, James T. Symanowski, Declan Walsh, Michael R. Grunwald, Aleksander L. Chojecki

Blood (2022) 140 (Supplement 1): 5279–5280.

https://doi.org/10.1182/blood-2022-156494

Published: 2022

Journal Articles

Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study

Aleksander L. Chojecki, Jai N. Patel, David M Foureau, James Symanowski, Xhevahire Begic, Michael Davis, Nury M Steuerwald, Sarah Norek, Srinivasa Reddy R. Sanikommu, Nilay A. Shah, Brittany Knick Ragon, Thomas G. Knight, Jing Ai, Michael R. Grunwald, Nilanjan Ghosh, Lawrence J Druhan, Belinda R. Avalos, Edward A. Copelan

Blood (2022) 140 (Supplement 1): 10534–10536.

https://doi.org/10.1182/blood-2022-160214

Published: 2022

Journal Articles

Impact of Polymorphisms in Pharmacokinetic Genes on Tyrosine Kinase Inhibitor (TKI) Tolerability in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Blood (2022) 140 (Supplement 1): 11530–11531.

https://doi.org/10.1182/blood-2022-166277

Published: 2022

Journal Articles

Self-Reported Distress Is Associated with Decreased Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia

Thomas G. Knight, James T. Symanowski, Jing Ai, Brittany Knick Ragon, Aleksander L. Chojecki, Nilay A. Shah, Srinivasa Reddy Sanikommu, Edward A. Copelan, Declan Walsh, Michael R. Grunwald, Patrick L Meadors

Blood (2022) 140 (Supplement 1): 8144–8145.

https://doi.org/10.1182/blood-2022-168973

Published: 2022

Journal Articles

HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

Blood (2022) 139 (10): 1452–1468.

https://doi.org/10.1182/blood.2021013443

Published: 2022

Includes: Supplemental data

Journal Articles

Clinical Characteristics and Outcomes of AML Patients Treated with Frontline CPX 351 or HMA/Venetoclax: A Single Institution's Experience

Aleksander L. Chojecki, Justin Arnall, Danielle Boselli, Kristyn Y. DiSogra, Allison Karabinos, Tommy Chen, Jing Ai, Thomas G. Knight, Brittany Knick Ragon, Nilay A. Shah, Srinivasa R. Sanikommu, James T Symanowski, Belinda R Avalos, Edward A. Copelan, Michael R. Grunwald

Blood (2021) 138 (Supplement 1): 1252.

https://doi.org/10.1182/blood-2021-149811

Published: 2021

Journal Articles

Incidence and Risk Factors Associated with Fatal Graft Vs Host Disease after Solid Organ Transplantation in United Network of Organ Transplant Database

Pavan Tenneti, Jiaxian He, Peter Lalli, Pranav Tenneti, Michael R. Grunwald, Edward A. Copelan, Belinda Avalos, Srinivasa Reddy R. Sanikommu

Blood (2021) 138 (Supplement 1): 4067.

https://doi.org/10.1182/blood-2021-154104

Published: 2021

Journal Articles

Acute Myeloid Leukemia Patients in Complete Remission with Positive Measurable Residual Disease Prior to Allogeneic Transplant Have Worse Outcomes, Similar to Active Disease Regardless of Conditioning Regimen Intensity and Post-Transplant Cyclophosphamide Administration

Pavan Tenneti, Jiaxian He, Brittany Knick Ragon, Nilay A. Shah, Jing Ai, Aleksander L. Chojecki, Thomas G. Knight, Belinda Avalos, Edward A. Copelan, Michael R. Grunwald, Srinivasa Reddy R. Sanikommu

Blood (2021) 138 (Supplement 1): 4907.

https://doi.org/10.1182/blood-2021-154011

Published: 2021

NARROW

Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL

Neighborhood Disadvantage Is Associated with Inferior Overall Survival for Acute Myeloid Leukemia Patients Treated with Standard Intensive Induction

MYC Pathway Upregulation Identified in Non-Responders to Hypomethylating Agents and Presents a Therapeutic Target in Acute Myeloid Leukemia

High Rate of Disease Progression in Patients with Low-Risk Myelofibrosis (MF) Enrolled in the Prospective, Real-World MOST Study

Socioeconomic Disadvantage Is Associated with Decreased Long-Term Survival in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia

A Real-World Evaluation of Risk Factors for Disease Progression in Patients with Polycythemia Vera (PV) Enrolled in REVEAL

Enhanced Support Services Including Nurse Navigation Mitigate Socioeconomic Disparities in the Treatment of Patients with Acute Lymphoblastic Leukemia

A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia

Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation

Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

Disease Progression and Leukemic Transformation in Patients With Lower-Risk Myelofibrosis (MF): An Analysis from MOST

Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL

Measuring the Incidence of Distress and Supportive Oncology Utilization Among Patients with Myeloproliferative Neoplasms: A Single Center Experience

Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study

Impact of Polymorphisms in Pharmacokinetic Genes on Tyrosine Kinase Inhibitor (TKI) Tolerability in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Self-Reported Distress Is Associated with Decreased Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia

HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

Clinical Characteristics and Outcomes of AML Patients Treated with Frontline CPX 351 or HMA/Venetoclax: A Single Institution's Experience

Incidence and Risk Factors Associated with Fatal Graft Vs Host Disease after Solid Organ Transplantation in United Network of Organ Transplant Database

Acute Myeloid Leukemia Patients in Complete Remission with Positive Measurable Residual Disease Prior to Allogeneic Transplant Have Worse Outcomes, Similar to Active Disease Regardless of Conditioning Regimen Intensity and Post-Transplant Cyclophosphamide Administration

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only